HeartSciences Inc. (HSCSW) stock
HSCSWNasdaqFinance ServicesFiscal year ends April 30Also trades as HSCS
$0.07−0.03 (-30.62%)
Close on Oct 30, 2026Market cap $15.89MP/E –Yield 0.00%
HeartSciences r&d expenses
Research and development expenses are spending on new products and technology.
HeartSciences's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.75M, down 33.9% year over year. For fiscal 2026 it was $2.84M, down 35.3% from the year before. The highest annual figure on record is $4.39M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $2.84M | -35.3% |
| FY2025 | Apr 30, 2025 | $4.39M | +52.4% |
| FY2024 | Apr 30, 2024 | $2.88M | +17.0% |
| FY2023 | Apr 30, 2023 | $2.46M | -18.0% |
| FY2022 | Apr 30, 2022 | $3.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027 | Jul 31, 2026 | $906.63K | -9.1% |
| Q4 FY2026 | Apr 30, 2026 | $476.21K | -48.7% |
| Q3 FY2026 | Jan 31, 2026 | $638.58K | -38.2% |
| Q2 FY2026 | Oct 31, 2025 | $727.03K | -39.4% |
| Q1 FY2026 | Jul 31, 2025 | $997.21K | -18.6% |
| Q4 FY2025 | Apr 30, 2025 | $929.09K | -11.2% |
| Q3 FY2025 | Jan 31, 2025 | $1.03M | +102.8% |
| Q2 FY2025 | Oct 31, 2024 | $1.20M | +58.3% |
| Q1 FY2025 | Jul 31, 2024 | $1.22M | +116.6% |
| Q4 FY2024 | Apr 30, 2024 | $1.05M | +95.7% |
| Q3 FY2024 | Jan 31, 2024 | $509.51K | -20.8% |
| Q2 FY2024 | Oct 31, 2023 | $757.30K | -10.8% |
| Q1 FY2024 | Jul 31, 2023 | $565.63K | +30.3% |
| Q4 FY2023 | Apr 30, 2023 | $534.44K | -60.6% |
| Q3 FY2023 | Jan 31, 2023 | $643.26K | -8.0% |
| Q2 FY2023 | Oct 31, 2022 | $848.98K | +55.6% |
| Q1 FY2023 | Jul 31, 2022 | $434.20K | +8.2% |
| Q4 FY2022 | Apr 30, 2022 | $1.36M | – |
| Q3 FY2022 | Jan 31, 2022 | $699.02K | – |
| Q2 FY2022 | Oct 31, 2021 | $545.77K | – |
| Q1 FY2022 | Jul 31, 2021 | $401.11K | – |